IQVIA (NYSE:IQV) Hits New 12-Month High – Here’s Why

IQVIA Holdings Inc. (NYSE:IQV) hit a new 52-week high during trading on Wednesday . The stock traded as high as $277.40 and last traded at $273.6540, with a volume of 74125 shares. The stock had previously closed at $270.09.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. TD Cowen lifted their price objective on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, September 12th. Finally, Stifel Nicolaus raised their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $248.00.

IQVIA Price Performance

The business’s 50-day simple moving average is $245.20 and its two-hundred day simple moving average is $200.94. The stock has a market cap of $44.64 billion, a price-to-earnings ratio of 33.66, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter last year, the business posted $2.81 EPS. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.56 earnings per share for the current year.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 15,581 shares of company stock worth $3,796,021. Company insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Compass Financial Management LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $27,000. Financial Freedom LLC purchased a new position in shares of IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA in the first quarter valued at approximately $25,000. Elevation Wealth Partners LLC increased its position in shares of IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 105 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new stake in IQVIA during the fourth quarter worth $35,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.